BMO Capital analyst Kostas Biliouris downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a price target of $48, up from $35, after the company agreed to be acquired by Novartis (NVS) for $48 per share or $1.4B. BMO expects a “smooth” deal closure by Q4 without material antitrust concerns.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML: